论文部分内容阅读
作者对20例中等严重的稳定型心绞痛病人,应用新型钙通道阻滞剂双苯吡乙胺(bepridil)进行单盲对照试验,观察其抗心绞痛的临床及血流动力学变化。单盲对照试验前4周(对照期)及试验后2周(安慰撤药期)服同剂型安慰剂。第5～10周为药物治疗期,各以该药50、100和150mg的剂量,每日3次,连服2周。在开始前、对照期第2及4周末、治疗期末及安慰撤药期1周末均进行分级踏车运动试验。其中13例在对照期末、治疗期末以及安慰撤药期末进行运动应激放射性核素心室造影。
The author of 20 patients with moderate and severe stable angina patients, the application of a new calcium channel blocker bepridopyr dipyridamole (bepridil) for a single-blind controlled trial of anti-angina clinical and hemodynamic changes. Four weeks before the single-blind control trial (control period) and two weeks after the test (placebo withdrawal period) were dosed with placebo. Weeks 5 to 10 for the drug treatment period, the dose of 50,100 and 150 mg of the drug, 3 times a day, and even for 2 weeks. Before the start of the control period, the 2nd and 4th weekend, the end of the treatment and the withdrawal phase of the weekend were graded treadmill exercise test. Thirteen patients underwent exercise stress radionuclide ventriculography at the end of the control period, the end of the treatment period and the end of the withdrawal period.